MedTrace Logo

ABO-GLYC in Type 2 Diabetes

NCT03568409 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2022-06-30

No results posted yet for this study

Summary

Evaluation of the improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.

Conditions

  • Type2 Diabetes

Interventions

DEVICE

ABO-GLYC

3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.

OTHER

ABO-GLYC Placebo

3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.

Sponsors & Collaborators

  • Latis S.r.l.

    collaborator INDUSTRY

  • Fondazione Edmund Mach

    collaborator OTHER

  • Aboca Spa Societa' Agricola

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568409 on ClinicalTrials.gov